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ABSTRACT
Bisphosphonates are important treatments for bone
metastases. Considerations for optimizing the clinical
benefits of bisphosphonates include efficacy, compli-
ance,andsafety.Severalbisphosphonatesareapproved
for clinical use; however, few have demonstrated broad
efficacy in the oncology setting and been compared di-
rectly in clinical trials. Among patients with bone me-
tastases from breast cancer, the efficacy of approved
bisphosphonateswasevaluatedinaCochranereview,
showing a reduction in the risk of skeletal-related
events (SREs) ranging from 8% to 41% compared
with placebo. Between-trial comparisons are con-
founded by inconsistencies in trial design, SRE defi-
nition, and endpoint selection. Zoledronic acid has
demonstrated clinical benefits beyond those of pam-
idronateinahead-to-headtrialthatincludedpatients
with breast cancer or multiple myeloma. Compliance
andadherencealsohaveeffectsontreatmentefficacy.
In a comparison study, the adherence rates with oral
bisphosphonates were found to be significantly lower
comparedwiththoseofintravenousbisphosphonates.
The safety profiles of oral and intravenous bisphos-
phonates differ. Oral bisphosphonates are associated
with gastrointestinal side effects, whereas intrave-
nous bisphosphonates have dose- and infusion rate–
dependent effects on renal function. Osteonecrosis of
the jaw is an uncommon but serious event in patients
receiving monthly intravenous bisphosphonates or
denosumab. The incidence of this event can be re-
duced with careful oral hygiene. A positive benefit-
risk ratio for bisphosphonates has been established,
and ongoing clinical trials will determine whether in-
dividualized therapy is possible. The Oncologist 2010;
15:1147–1158
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Malignant bone disease is common in patients with ad-
vanced solid tumors or multiple myeloma. Among patients
with lung cancer, bladder cancer, or melanoma, approxi-
mately 40% develop bone metastases during the course of
their disease [1]. Breast cancer (BC) and prostate cancer
(PC) have an especially high potential for metastasis to
bone, which occurs in approximately 75% of patients with
stageIVdisease[1].Becausethesepatientsmayhaveame-
diansurvivalofseveralyearsafterthedevelopmentofbone
metastases, they have a long-term risk of developing skel-
etal-related events (SREs) including pathologic fractures,
spinal cord compression, the requirement for surgery (in-
cludingvertebroplasty,kyphoplasty,andcementoplasty)or
radiotherapytobone,andhypercalcemiaofmalignancy.In-
deed,intheabsenceofbone-specifictherapies,SREsoccur
in 46%–68% of patients with bone metastases from solid
tumors, and patients may experience multiple SREs [2–4].
Furthermore, the risk of subsequent SREs increases after
the first SRE [5, 6]. These SREs can have negative conse-
quencesforpatients’functionalindependence.Amongmen
withPCandwomenwithBC,thereareconsistentdecreases
in physical and emotional well-being after SREs [7, 8].
Moreover, in patients with PC or BC, pathologic fractures
have been associated with reduced survival [9]. Therefore,
prevention of SREs is an important therapeutic goal.
Inrecentyears,treatmentinnovationshavesignificantly
extended survival, even for patients with stage III or IV
lung cancer and castration-resistant PC [10, 11]. However,
prolonging survival may increase the likelihood that cancer
and its treatment effects on the skeleton will manifest in
skeletal morbidity within patients’ lifetimes. Therefore, an
important goal of therapy is to preserve patients’ bone
health, thereby preserving their functional independence to
the extent possible throughout the course of the disease.
The therapeutic repertoire for managing skeletal morbidity
and slowing the erosion in quality of life includes analge-
sics, radiotherapy, surgery, and bisphosphonates. Bisphos-
phonates can reduce bone pain, analgesic use, and need for
radiationtobone[12].However,bisphosphonatesalsotreat
the underlying cause of SREs—malignant osteolysis—and
can therefore delay the onset and reduce the incidence of
SREs [13, 14]. Although several bisphosphonates are ap-
proved for clinical use, relatively few have demonstrated
efficacy for broad application in the oncology setting, and
the majority of bisphosphonates are approved only for use
inBCmetastatictobone(Figure1).Moreover,fewofthese
agents have been compared directly in clinical trials, and
between-trial comparisons are confounded by inconsisten-
cies in trial design, SRE definition, and endpoint selection.
In optimizing the clinical benefits of bisphosphonates, im-
portantconsiderationsforbisphosphonateselectioninclude
not only efficacy but also safety profiles and compliance.
EFFICACY OF BISPHOSPHONATES
Bisphosphonateshavebeenrecommendedforthetreatment
of primary bone lesions from multiple myeloma or bone
metastases from solid tumors [15–18]. Although bisphos-
phonates are administered systemically, they are deposited
at sites of active bone remodeling. Bisphosphonates accu-
mulate in the bone and are ingested by osteoclasts during
bone resorption, wherein they inhibit osteolysis [19]. There
are two classes of bisphosphonates with different mecha-
nisms of action: non–nitrogen-containing and nitrogen-
containing[19].Non–nitrogen-containingbisphosphonates
such as clodronate are metabolized by osteoclasts to cyto-
toxic compounds. Nitrogen-containing bisphosphonates
such as zoledronic acid, pamidronate, and ibandronate in-
hibitakeyenzymeinthemevalonatepathway,inducingap-
optosis of osteoclasts. Both classes are currently used for
the treatment of bone metastases in patients with cancer.
Clinical trials providing evidence for the efficacy of these
agents have used similar definitions of skeletal morbidity,
but not all trials have selected robust clinical endpoints that
provide objective and quantitative measurements of patient
benefit.Forexample,painscores,analgesicuse,andquality
of life associated with bone metastases are difficult to ob-
jectively measure and may be confounded by observer bias
[6]. These clinical endpoints are, therefore, not easily com-
parable in different patient populations. In contrast, SREs
canbeobjectivelymeasuredandprovideclinicallyrelevant
information for the evaluation of bisphosphonates. Indeed,
theSREhasbeenusedasanexampleofaclinicallyrelevant
composite endpoint by the U.S. Food and Drug Adminis-
tration (FDA) [20]. However, the definition for SREs has
varied. Skeletal morbidity rate ([SMR] mean SRE rate per
person-year) is a less robust endpoint in clinical trials be-
cause it assumes a constant event rate for all patients and
cannot adjust for inter- and intrapatient variations in SRE
Figure1. Approvedbisphosphonateindicationsintheoncol-
ogy setting. Abbreviations: HCM, hypercalcemia of malig-
nancy; IV, intravenous. (Note: In the United States, prostate
cancer must have progressed despite hormone therapy.)
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statistical models, based on various statistical assumptions,
have been used in clinical trials, including multiple event
analyses such as Andersen-Gill that provide robust meth-
odology for reporting treatment effects by adjusting for
variability in event rates over time [6].
Breast Cancer
Guidelines from the American Society of Clinical Oncol-
ogy (ASCO) recommend intravenous pamidronate or
zoledronic acid in patients with bone metastases from BC,
the only two agents approved for that indication in the
United States [17]. Both have produced significant reduc-
tions in the risk of SREs compared with placebo in this set-
ting [2, 21]. In the only head-to-head phase III trial of
bisphosphonates in this setting, 4 mg of zoledronic acid
demonstrated efficacy at least comparable to and some sig-
nificant benefits beyond those of 90 mg of pamidronate in
patients with bone lesions from multiple myeloma or BC
[22, 23]. In the subset of patients with BC, Andersen-Gill
multiple event analysis revealed that zoledronic acid re-
duced the risk of developing SREs by an additional 20%
compared with pamidronate (p  .025) [3, 4, 23, 24]. The
efficacy of bisphosphonates in patients with BC was also
evaluatedinaCochranereview,whichconfirmedtheutility
of this class of agents to prevent SREs from bone metasta-
sesandreportedarangeofSREriskreductionsforbisphos-
phonates [25]. Versus placebo, reported risk reductions
were41%forintravenouszoledronicacid,23%forintrave-
nous pamidronate, and 18% and 14% for intravenous and
oral ibandronate, respectively. The risk reduction with oral
ibandronate fell short of statistical significance, as did the
riskreductionwithoralclodronateinmostofthecitedstud-
ies. However, differences in patient populations, trial de-
signs, SRE definitions, and endpoint selection confound
any between-trial comparisons. Overall, these data indicate
a benefit for all approved agents.
Among the oral bisphosphonates studied in patients
with bone metastases from BC, there was a significant re-
ductionintheskeletalmorbidityperiodrate(numberof12-
week periods with new SREs) with ibandronate versus
placebo; however, this assessment cannot be compared
with SMR endpoints [26]. The remaining two clinical end-
points, proportion of patients with an SRE and time to first
SRE, were not significantly different between oral iban-
dronate and placebo (Table 1) [2, 21, 25–28]. Oral clodronate
has also demonstrated benefits in patients with metastatic
BC. Efficacy results for the prevention of SREs, however,
have been inconsistent between studies, especially with re-
gard to bone pain endpoints and incidence of radiotherapy
to bone [25, 28–30]. In a comparison study, intravenous
pamidronate was found to be more effective than oral clo-
dronate in improving pain scores (p  .05) [31].
Prostate Cancer
Among patients with bone metastases from PC, zoledronic
acid is the only bisphosphonate to provide statistically signif-
icantanddurablereductionsintheriskofSREsversusplacebo
in a randomized, controlled trial and to have received wide-
spread regulatory approval. In the phase III trial, patients with
bone metastases from PC (N  643) were randomized to re-
ceiveeitherzoledronicacidorplaceboforupto2years[4,32].
At 24 months compared with placebo, zoledronic acid signif-
icantly reduced the proportion of patients with an SRE (49%
versus38%,respectively;p.028)andtheSMR(1.47versus
0.77 SREs per year, respectively; p  .005), and increased
meantimetofirstSRE(321versus488days,respectively;p
.009) [4]. Zoledronic acid also reduced the risk of SREs by
36% versus placebo (Andersen-Gill multiple event analysis;
p  .002) [3, 4, 23, 24]. Moreover, zoledronic acid provided
long-term reductions in bone pain versus placebo (p  .05 at
21 and 24 months [33]. In contrast, in randomized, placebo-
controlledtrials,pamidronateandclodronatefailedtodemon-
strate significant benefits in these endpoints versus placebo
[34]. Similar results have been reported for oral clodronate
[35].
Other Solid Tumors
Zoledronic acid has been shown to reduce SREs in patients
with bone metastases from lung cancer, kidney cancer, and a
broadrangeofothersolidtumors.InthephaseIIItrial,patients
with lung cancer or other solid tumors (N  773) were ran-
domized to receive either zoledronic acid or placebo for up to
21months[3].At21months,4mgofzoledronicacidreduced
theproportionofpatientswhodevelopedanon-studySREin-
cluding hypercalcemia of malignancy (39% versus 48% with
placebo; p.039), significantly delayed the time to first SRE
(236 days versus 155 days with placebo; p  .009), and re-
ducedtheSMR(1.74versus2.71SREsperyearwithplacebo;
p  .012). In an Andersen-Gill analysis, zoledronic acid sig-
nificantly reduced the risk of SREs by 31% compared with
placebo(p.003)[3,4,23,24].Inaretrospectivesubsetanal-
ysis from this trial of patients with renal cell carcinoma (n 
74),zoledronicacidsignificantlyreducedtheproportionofpa-
tients with an SRE at 9 months (37% versus 74% for placebo;
p  .015) and significantly prolonged the time to first SRE
(median not reached versus 72 days for placebo; p  .006)
[36]. Multiple event analysis also demonstrated that
zoledronic acid reduced the risk of SREs by 61% versus pla-
cebo (p  .008) [36]. Such randomized placebo-controlled
data have not been reported for other bisphosphonates.
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WITH BISPHOSPHONATES
Bone pain is usually the earliest and most common symp-
tom of bone metastases, and bone metastases often are not
diagnosed until after the onset of bone pain [37]. However,
bonepaincanhavedebilitatingeffectsonapatient’squality
oflife,andtreatmentafterpaindevelopsmaynotbetheop-
timal strategy. Therefore, identification of patients at risk
for bone metastases, earlier diagnosis, and earlier treatment
for bone metastases may be more beneficial.
In the adjuvant BC setting, aromatase inhibitor (AI) use is
increasing, and AIs have been associated with accelerated
bone loss and increased fracture risk [38]. In fact, bone loss
associated with AIs may occur at a twofold higher rate than
thatobservedinhealthypostmenopausalwomen(PMW)[39].
Among the oral bisphosphonates, 3 years of clodronate, 1,600
mg/day, reduced treatment-induced bone loss of the lumbar
spine in 73 patients with BC compared with control [40].
Risedronate, 35 mg once weekly for 24 months, stabilized
bone mineral density (BMD) at the hip from baseline and cur-
tailed spinal BMD loss versus placebo (2.8% versus 4.8%, re-
spectively, from baseline) in PMW with BC receiving an AI
[41].Inanotherstudywithcyclicrisedronate(30mg/dayfor2
weeksfollowedby10weeksofnodrug)for2yearsinpatients
with BC and treatment-induced menopause, risedronate in-
creased BMD versus placebo (p  .041 for both) [42]. How-
ever, weekly risedronate failed to prevent lumbar spine BMD
loss in patients with BC [43]. Ibandronate, 150 mg/day, in-
creased BMD from baseline in osteopenic PMW with BC re-
ceiving anastrozole (n50) during 2 years of treatment [44].
Intravenous pamidronate (60 mg every 3 months) inhibited
bone loss versus placebo in 40 premenopausal women for 1
year but did not improve BMD versus baseline [45]. Intrave-
nous zoledronic acid (4 mg every 6 months) for 3 years stabi-
lized BMD in premenopausal women with BC treated with
endocrine therapy (n  404) [46]. At the 5-year follow-up,
BMD continued to decrease with placebo, whereas it contin-
ued to increase versus baseline with zoledronic acid. In an-
other study with immediate or delayed treatment with
zoledronic acid, 4 mg biannually, for 5 years in patients with
BC receiving letrozole, immediate zoledronic acid increased
BMD at 12 months compared with delayed treatment (p 
.0001 for both) [47]. Therefore, bisphosphonates can reduce
cancer treatment–associated bone loss in BC patients, and
Table 1. Efficacy of bisphosphonates in placebo-controlled studies of patients with breast cancer
Agent versus placebo (p)
IV zoledronic
acid 4 mg [21]
IV pamidronate
90 mg [2]
IV ibandronate
6 mg [27]
Oral ibandronate
50 mg [26]
Oral clodronate
1,600 mg [25,28]
d
Randomized patients, n
a 228 754 312 564 185
Endpoint
Patients with  1
SRE, %
30.7 versus 52.2
(.001)
53 versus 68
(.001)
50.6 versus 62.0
(.052)
45.3 versus 52.2
(.122)
Time to first SRE NR versus 360
days (.004)
12.7 versus 7.0
mo (.001)
50.6 versus 33.1
wk (.018)
90.3 versus 64.9
wk (.089)
9.9 versus 4.9 mo
(.022)
Skeletal morbidity
rate
2.5 versus 4.0
(.001)
c 218.6 versus
304.8/100 patient-
years (.001)
SRE rate ratio
b 0.57 (.016)
c
Skeletal morbidity
period rate
1.19 versus 1.48
(.004)
c 0.95 versus 1.18
(.004)
c
Multiple event
analysis, RR
0.56; 95% CI:
0.363, 0.867;
(.009)
Poisson regression
analysis, HR
0.62; 95% CI: 0.48,
0.79; (.001)
IV bisphosphonates were administered every 3–4 weeks, and oral bisphosphonates are administered daily.
aThe randomized patients are for indicated arm and placebo.
bSRE rate in the zoledronic acid group/SRE rate in the placebo group.
cPrimary endpoint.
dPrimary endpoint was proportion of patients who experienced one or more of the following: hypercalcemia, vertebral or
nonvertebral fracture, and requirement for radiotherapy for bone pain.
Abbreviations: CI, confidence interval; HR, hazard ratio; IV, intravenous; NR, not reached; RR, relative risk; SRE, skeletal-
related event (pathologic fractures, spinal cord compression, requirement for surgery or radiotherapy to bone, and
hypercalcemia of malignancy).
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deprivation therapy (ADT) for PC, although no treatments are
currently approved in the United States or Europe for these
specific indications [48–51].
Guidelines have been published regarding the use of
bisphosphonates in BC. One expert panel recommends that
bisphosphonate therapy should be started in any patient initi-
ating or receiving AI therapy with a T-score less than 2.0 or
ifotherriskfactorsarepresent[52].ABritishexpertpanelrec-
ommended bisphosphonate therapy in women experiencing
premature menopause receiving AIs if the annual rate of bone
loss exceeds 4% at lumbar spine or total hip sites, or if there is
a history of vertebral fracture or T-score less than 1.0 [53].
TherecommendationsforPMWweresimilar,buttheT-score
threshold was reduced to less than 2.0. An international ex-
pert panel made similar recommendations, but also recom-
mended amino-bisphosphonates for patients with bone
metastases from BC, and zoledronic acid for patients with
bone metastases from other solid tumors [54].
InexploratoryanalysesofthephaseIIItrials,zoledronic
acid produced a more profound reduction versus placebo in
patients with PC or versus pamidronate in patients with BC
in the proportion of patients with one or more SREs and in
patients with no pain at baseline compared with patients
with pain at baseline [55, 56]. Moreover, zoledronic acid
also reduced the SMR by a greater extent in patients with
PC and no pain at baseline (49%) compared with patients
who had pain at baseline (39%) [56]. Among patients with
BC and no prior fractures at baseline, zoledronic acid re-
duced the SMR by a greater extent compared with patients
who had a prior fracture at baseline (by 0.33 and 0.78, re-
spectively) [21].
Pain levels often increase during disease progression
and may indicate advancing bone disease. A greater num-
ber of bone metastases results in an increased risk of SREs.
Indeed,patientswithsolidtumorsandmorethanthreebone
metastases have an approximately 1.5-fold increase in the
risk of SREs [57]. Furthermore, after patients experience
SREs, they are at a higher risk of subsequent SREs. Among
patients with bone metastases from BC, a first SRE in-
creases the risk of a subsequent SRE twofold [58]. More-
over, pathologic fractures increase risk of death by 23%–
32% in patients with bone metastases from PC or BC,
respectively [9].
Bisphosphonates may have effects beyond bone health.
Preclinical results demonstrated that zoledronic acid, pam-
idronate, clodronate, and ibandronate exhibit antitumor ac-
tivity in BC cell lines and animal models of early BC
disease [59, 60]. However, clinical studies have yielded
mixedresults.Twostudiessuggestasurvivalbenefitforpa-
tients receiving clodronate as adjuvant therapy for breast
cancer [61, 62]. However, a meta analysis of seven clinical
studies evaluating oral clodronate (1,600 mg/day for 2–3
years) versus placebo or no additional treatment found no
significant difference in overall survival or bone-metasta-
sis–free survival in patients with either early or advanced
BC [63]. Pamidronate, 90 mg every 4 weeks, has shown
similarresultsversusplaceboinpatientswithadvancedBC
[64, 65]. Overall disease benefits have not been reported
with ibandronate. Zoledronic acid reduced the risk of
diseaseprogression(hazardratio[HR] 0.64;95%con-
fidenceinterval[CI]:0.46,0.91;p  .01)andproduceda
trend toward reduced risk of death (HR  0.60; 95% CI:
0.32; 1.11; p .11) versus no zoledronic acid in pre-
menopausal patients receiving endocrine therapy for
earlyBC[66].Arecentexploratoryanalysisofdatafrom
three companion studies of zoledronic acid in combina-
tion with adjuvant letrozole therapy in postmenopausal
women with early BC shows significantly improved dis-
ease-free survival in the ZO-FAST study [67], but no
clear benefit in the other two studies [68]. This is primar-
ily a result of the low rates of disease recurrence, differ-
ences in the length of follow-up, and lack of follow-up
after discontinuation in one study, among other con-
founding factors. Results from these and other clinical
trialsindicatingthattheantitumoreffectsofbisphospho-
nates may translate into clinical benefits have been re-
cently reviewed [69].
CLINICAL BENEFITS OF CONTINUING
BISPHOSPHONATE TREATMENT IN CANCER
PATIENTS WITH BONE METASTASES
Data from the placebo-controlled arms of bisphosphonate
trials have revealed that patients are at risk for SREs
throughout the course of their advanced disease and that
long-term treatment may therefore be needed [3, 4, 23].
However,resultsfrombisphosphonatestudiesthatfocuson
clinical benefits that may occur after the first years of treat-
ment are scarce. Intravenous ibandronate (6 mg every 3–4
weeks for up to 2 years) in patients with bone metastases
fromBChassignificantlyreducedthemeannumberofnew
SREs by 38% (p  .032) and significantly increased the
time to a first new SRE (p  .018) compared with placebo
[27]. However, this trial did not assess the possible benefits
of ibandronate during the second year of treatment sepa-
rately and, therefore, presents a limitation on assessing the
clinical benefits beyond the first year. Intravenous pamid-
ronate (90 mg every 3–4 weeks for up to 2 years) signifi-
cantlyreducedtheincidenceanddelayedtheonsetofSREs
compared with placebo in patients with bone metastases
from BC, but the same assessment limitation as in the iban-
dronate study is present [2]. Exploratory analyses of the
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PC demonstrated that the risk of SREs in patients with PC
receiving zoledronic acid during months 16 to 24 was sig-
nificantly reduced by 53% compared with the placebo
group(HR0.467;p.022)[70].Thisriskreductionwas
greater than that observed during the first 15 months of the
study (HR  0.643; p  .004). During months 16 to 24 of
treatment, zoledronic acid also continued to provide signif-
icant reductions in proportion of patients with an SRE (p 
.017), time to first SRE (p  .036), and SMR (p  .016)
compared with placebo [70]. Exploratory analyses of the
subset of patients with bone metastases from BC who en-
tered the second year of treatment demonstrated that
zoledronicacidsignificantlyreducedtheriskofdeveloping
an SRE by an additional 41% compared with pamidronate
(p.026)duringthesecondyearoftreatment[71].During
the second year of therapy, zoledronic acid also continued
to provide reductions in the proportion of patients with an
SRE(p.072),timetofirstSRE(p.067),andSMR(p
.058) compared with pamidronate [71].
Bisphosphonate treatment continues to provide clinical
benefits after a patient experiences an SRE, as shown by
further exploratory analyses. A multiple event analysis of
data from patients with PC receiving zoledronic acid
showed that when the first SRE is excluded, there is a
greater risk reduction of subsequent SREs compared with
theplacebogroup(HR0.601;p.011)[70].Zoledronic
acid also significantly reduced the proportion of patients
who experienced a second SRE (p  .017) and the SMR
afterexcludingthefirstevent(p.014)[70].Furthermore,
the median time to a second SRE was significantly delayed
among patients with PC receiving zoledronic acid com-
pared with the placebo group (p  .006) [70]. Among pa-
tients with PC who had experienced an SRE before study
entry, zoledronic acid, 4 mg, reduced the proportion of pa-
tients who experienced an on-study SRE (41%versus 51%,
respectively; p  .215) and provided a significant 65% rel-
ative reduction in mean SMR compared with placebo (0.80
versus 2.30, respectively; p  .036) [70]. Among patients
with bone lesions from multiple myeloma or bone metasta-
ses from BC, zoledronic acid produced a trend toward a
lowerproportionofpatientswhoexperiencedasecondSRE
(p  .170) and the SMR after excluding the first event (p 
.105)comparedwithpamidronate[72].However,inthepa-
tients who had experienced an SRE before study entry,
zoledronic acid significantly reduced the proportion of pa-
tients who experienced an on-study SRE compared with
pamidronate (54% versus 61%, respectively; p  .039) and
theSMRby24%relativetopamidronate(1.22versus1.61;
p  .038).
PRACTICAL CONSIDERATIONS OF
BISPHOSPHONATE TREATMENT
Four parameters should be considered when selecting a
bisphosphonate: efficacy, compliance, adherence, and
safety. Efficacy results presented in the previous sections
show that, among patients with bone metastases from BC,
the approved intravenous and oral bisphosphonates all re-
duce the risk of SRE compared with placebo [25]. How-
ever, broad generalizations regarding the relative efficacy
of bisphosphonates should be avoided because direct com-
parative studies between bisphosphonates (other than
pamidronate versus zoledronic acid) have not been done.
AmongpatientswithPC,lungcancer,orothersolidtumors,
zoledronicacidistheonlyapprovedbisphosphonateforthe
treatment of bone metastases.
Compliance (administration regimen implemented as
indicated on product label, e.g., with regard to dosing fre-
quency), adherence (degree to which patients follow physi-
cian’s advice, e.g., with regard to the duration of therapy),
and convenience of administration are important consider-
ations when selecting a bisphosphonate. For example, oral
bisphosphonates may be taken at home, whereas intrave-
nous bisphosphonates require a visit to the doctor’s office
orhospital.However,thetabletsoforalclodronatearelarge
andmaybehardforpatientstoswallow,causingpatientsto
discontinue treatment [73], but oral ibandronate tablets are
smaller. Patients must also fast overnight before taking an
oral bisphosphonate (because food interferes with absorp-
tion), remain upright, and continue to fast after administra-
tion from at least 30 minutes for up to 2 hours—depending
on the agent—to minimize the risk of gastrointestinal ad-
verse events [73]. The requirements for administration of
oral bisphosphonates are associated with reduced compli-
ance and may lead to reduced adherence and, therefore, to
suboptimal efficacy [74, 75]. Furthermore, patient adher-
ence with the prescribed treatment regimen cannot be ade-
quately monitored with oral agents. A retrospective
analysis of insurance claims in Germany showed that the
median duration of therapy was 112 days for oral bisphos-
phonates[76].After3monthsoftreatment,44%ofpatients
had stopped therapy, and, after 6 months, 64% of patients
had stopped therapy (Figure 2A) [76]. In contrast, adher-
ence with intravenous bisphosphonates is generally high,
withapproximately90%ofpatientsremainingontreatment
after 6 months (Figure 2B) [4, 23, 77]. A comparison of in-
travenousversusoralbisphosphonateadherenceratesinpa-
tients with advanced cancer showed that at 6 months oral
bisphosphonates had a significantly lower adherence rate
compared with intravenous bisphosphonates (36% versus
92%; p  .0012) [77]. An intravenous treatment allows
greater contact with healthcare providers and promotes ad-
1152 Bisphosphonates and Optimizing Clinical Benefitsherence mostly through provider attention and proactive
management. Patient adherence with an intravenous regi-
menisthenknowntothehealthcareproviders,andthephy-
sicianscanbeassuredthattheirpatientswillreceivethefull
efficacy afforded by the treatment.
Safety considerations among patients who receive
oral bisphosphonates relate to gastrointestinal side ef-
fects. In clinical trials, the incidences of diarrhea, dys-
pepsia, nausea, and esophagitis have typically been
higher in the oral bisphosphonate group compared with
the placebo group [26, 73]. In contrast, safety consider-
ations among patients who receive intravenous bisphos-
phonates relate to renal function, and osteonecrosis of
the jaw (ONJ). All intravenous bisphosphonates are as-
sociated with dose- and infusion rate–dependent effects
on renal function, and monitoring of serum creatinine
levelsisrecommendedtoensurerenalsafety[74].There-
fore, the product labels for zoledronic acid and pamid-
ronate recommend checking serum creatinine levels
before each infusion [78–80]. In patients with decreased
renal function, the product label for zoledronic acid rec-
ommends appropriate dose modifications (Table 2) [78].
These modifications achieve the same exposure to
zoledronic acid as that in patients with a creatinine clear-
anceof75ml/min.Doseadjustmentsforpatientswithre-
duced renal function are also included in the product
label for ibandronate (Table 2) [80]. Additionally, mild
to moderate acute-phase reactions (flu-like symptoms)
may occur, typically only after first infusion, and pa-
tients may stop treatment. However, acute-phase reac-
tions are usually self-limited and manageable with
nonsteroidalanti-inflammatoryagentsoracetaminophen
[81].
Recently,exposedboneinthejaw—ONJ—hasbeenre-
ported as an uncommon event among patients with cancer
whose treatment includes a monthly intravenous bisphos-
phonate [81–88]. Furthermore, ONJ has been reported in a
very small number of patients who were receiving oral
bisphosphonates for noncancer indications [82, 86, 87]. In
oneretrospectivestudy,in4,835patientswithmultiplemy-
eloma, BC, or PC treated with intravenous bisphospho-
nates, 0.7% developed ONJ [89]. In another retrospective
study of 1,338 patients with BC treated with intravenous
bisphosphonates,16(1.2%)developedONJ[84].Intwore-
cent prospective studies in patients with solid tumors or
Figure 2. Adherence of approved bisphosphonate treatments by route of administration. (A): Oral bisphosphonates except for
ibandronate. Adapted from Hoer A, Goethe H, Barghout V et al. Low persistency with oral bisphosphonates in cancer patients
[poster]. Presented at: 5th European Oncology Nursing Society Spring Convention; April 20–22, 2006; Innsbruck, Austria; Ab-
stract 2, with permission. (B): Intravenous bisphosphonates. Data from Mangiapane S, Hoer A, Gothe H et al. Higher persistency
with i.v. bisphosphonates in patients with bone metastasis [abstract]. J Clin Oncol 2006;24(suppl):698s. Abstract 18623.
Table 2. Recommended zoledronic acid and ibandronate
dose reductions in patients with decreased renal function
Baseline creatinine
clearance, ml/min
ZOL dose,
a
mg/infusion
time
IBN dose,
b
mg/infusion
time
60 4.0/15 minutes 6.0/15 minutes
50–60 3.5/15 minutes 6.0/15 minutes
40–49 3.3/15 minutes 6.0/1 hour
30–39 3.0/15 minutes 6.0/1 hour
30 2.0/1 hour
aDoses calculated to achieve an area under the curve of
0.66 mg-h/ml with a creatinine clearance of 75 ml/min
(using Cockcroft-Gault formula). Data from zoledronic
acid prescribing information [78].
bAdministration every 3 to 4 weeks. Data from
ibandronate summary of product characteristics [80].
Abbreviations: ZOL, zoledronic acid; IBN, ibandronate.
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incidenceofONJinpatientsreceivingdenosumabwassim-
ilar to that of patients receiving zoledronic acid (1.1% and
1.3%, respectively, in multiple myeloma or other solid tu-
mors; 2.0% and 1.4%, respectively, in BC) [90, 91]. Iden-
tified risks for ONJ included dental extractions (HR 
53.19; p  .0001), treatment with zoledronic acid (HR 
15.01; p  .0037), and treatment with pamidronate fol-
lowed by zoledronic acid (HR  4.00; p  .078). Other
studies have shown that dental extractions or surgery may
be an inciting event for ONJ [92, 93]. Moreover, a recent
study showed that preventive dental measures (such as
those of Weitzman et al [94]) before the initiation of
bisphosphonate treatment decrease the occurrence of ONJ
(0.7%versus3.0%for“after”versus“before”theintroduc-
tion of preventive dental measures, per protocol analysis)
[95]. Guidelines from recent multidisciplinary panels rec-
ommend that patients with cancer have preventive dental
measures before the initiation of bisphosphonate therapy
and be encouraged to maintain good oral hygiene [94, 96].
Patients may have routine dental hygiene and restorative
procedures during bisphosphonate therapy, but the least in-
vasiveproceduresshouldbeused.Aconservativeapproach
to the management of ONJ is recommended and includes
oral rinses, antibiotics, pain control, and limited debride-
ment by dental professionals. Current trials have been de-
signed to monitor oral health, and additional prospective
data should be forthcoming.
DISCUSSION
An important goal of therapy for bone metastases is to pre-
serve patients’ physical functioning and quality of life by
preventing SREs after diagnosis of bone metastases. Intra-
venous bisphosphonates allow monitoring adherence to
therapy.Inallsolidtumors,thebenefitsofbisphosphonates
are likely to continue throughout an approximately 2-year
period. In fact, the risk reductions for SREs were even
greater during patients’ second year of therapy compared
with those for the overall patient population in the first year
of treatment in a study of zoledronic acid. Thus, ASCO
guidelines for use of bisphosphonates in patients with BC
recommend that treatment be continued as long as it is tol-
erated or until there is a substantial decline in patients’ per-
formance status [17].
Other cancer patients with bone metastases who are
benefiting from effective anticancer therapies may also
benefit from bisphosphonate therapy. Indeed, although the
current regulatory approval for zoledronic acid in the
United States stipulates that patients with bone metastases
from PC must have had disease progression despite ADT,
the National Comprehensive Cancer Network guidelines
encourage early intervention with intravenous bisphospho-
nates in men receiving ADT [15]. Moreover, benefits seem
to be especially profound before the onset of pain. How-
ever,theoptimaltimingfortheinitiationofbisphosphonate
treatment in this setting has not been established.
The recommended dose and schedule of bisphospho-
nate therapy have been established in registration trials,
although alternate treatment schedules for bisphospho-
nate therapy are under investigation. Several nonstand-
ard, intensive treatment regimens of intravenous
ibandronate have been evaluated in patients with meta-
staticbonediseaseforacutebonepainrelief,followedby
the approved monthly infusions [97–99]. Results from
these pilot studies suggest that alternate ibandronate
schedule provided acute pain relief, and that more flexi-
ble or individualized bisphosphonate treatment may pro-
vide clinical benefits. However, the efficacy of this
alternate dosing schedule has not been confirmed in a
large, randomized clinical trial.
An ongoing study of the cost-effective use of
bisphosphonates in metastatic bone disease, a compari-
sonofbonemarker–directedzoledronicacidtherapytoa
standard schedule (BisMARK), will determine whether
using bone marker levels to direct zoledronic acid treat-
mentiscomparablewiththecurrentfixedscheduleofev-
ery 3–4 weeks in patients with BC [100]. The primary
comparison is the frequency and timing of SREs. Sec-
ondary comparisons include quality of life and phar-
macoeconomics. Final trial results are not expected until
2013; however, interim results are eagerly awaited. Fi-
nally, the efficacy of monthly zoledronic acid will be
compared with administration every 12 weeks for up to
1 year in patients with bone metastases from BC
(OPTIMIZE 2). The primary endpoint is the time to first
SRE [101]. These clinical studies are evaluating whether
efficacycanbemaintainedusingalternatedosingschedules
that may increase the flexibility of treatment for patients
without compromising efficacy. The alternate schedules
could also reduce the number of infusions, thereby improv-
ing benefit-risk ratios. Currently, only the approved doses
and schedules of bisphosphonate therapy have established
efficacy and safety profiles, and any other regimens are in-
vestigational.
Inadditiontobisphosphonates,severalphaseIIIclin-
ical trials have examined the efficacy of denosumab, a
recombinant human monoclonal IgG2 antibody against
the receptor activator of nuclear factor-B ligand, for
prevention of SREs in patients with bone lesions from
cancer (Table 3) [90, 91, 102]. Overall, the results from
threetrialshaveshownthatmonthlydenosumab(120mg
subcutaneous) achieved the primary endpoint of statisti-
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travenous) for time to first SRE in patients with BC [91],
PC [102], and multiple myeloma and other solid tumors
(not BC or PC) [90], and was statistically superior to
zoledronic acid in the secondary endpoints in the first
two studies. Nevertheless, there was no statistical differ-
ence between denosumab and zoledronic acid for overall
survival,diseaseprogression,orbonepainimprovement.
Currently, in the oncology setting, the European Medi-
cines Agency (EMA) has approved denosumab (60 mg
subcutaneous every 6 months) in the treatment of bone
loss associated with hormone ablation in men with PC at
increased risk of fractures (defined as 70 years or 70
years with a BMD T-score at the lumbar spine, total hip,
or femoral neck less than 1.0, or a history of an osteo-
poroticfracture)[103],basedonasignificantdecreasein
vertebral fracture risk in the Hormone Ablation Bone
Loss Trial (HALT)-PC trial [104]. Denosumab also has
been approved for the treatment of postmenopausal os-
teoporosis [103] and has shown activity for treatment of
bone loss associated with AI therapy in postmenopausal
women with breast cancer based on the HALT-BC trial
[105].Otheroncologyindicationsfordenosumabareun-
der review by the FDA and EMA.
The role of the different antiresorptive agents in oncol-
ogy is likely to evolve with the emergence of denosumab
and the maturation of clinical trials investigating the poten-
tial anticancer benefits of bisphosphonates, especially
zoledronic acid.
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